meteneprost

9-deoxo-9-methylene-PGEs are possible solution to PGE stability problem; stable in aqueous media from pH 1 to 14 & have biological properties similar to corresponding PGEs; cpd tested for use as early pregnancy terminater & has low incidence of nausea & gastrointestinal side effects; note that cpd is derivative of both PGE2 & PGF2alpha; structure in first source

Also Known As:

9-deoxo-16,16-dimethyl-9-methylene-PGE2; 9-deoxo-16,16-dimethyl-9-methyleneprostaglandin E2; 9-deoxy-16,16-dimethyl-9-methylene-PGF2; 9-methylene-16,16-dimethyl PGE2; 9-methylene-PGE2; prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-16,16-dimethyl-9-methylene, (5Z,11 alpha,13E,15R)-

Networked: 5 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Related Diseases

1.	Inappropriate ADH Syndrome (SIADH) 12/01/1984 - "However the protocol followed did not provide any evidence for this, or any other explanation of the observed renal retention of Na+, Ca2+ and Mg2+. The results reported here indicate that 9-methylene-PGE2 may have a future use as a water diuretic agent in patients suffering from water retention and dilutional hyponatraemia such as seen in the syndrome of inappropriate antidiuretic hormone (AVP) release commonly known as SIADH or Schwartz-Bartter's Syndrome." 12/01/1984 - "As the prostaglandin analogue effectively blocked the antidiuretic effect of the AVP-administration it appears that 9-methylene-PGE2 may play a future role as a diuretic agent, especially in conditions characterized by water retention and dilutional hyponatremia such as SIADH."
2.	Hemorrhage 01/01/1988 - " In addition, a decrease in postabortal bleeding was noted among the group treated with Meteneprost. " 03/01/1986 - "Meteneprost appears to do so with minimal gastrointestinal side-effects and with a low risk of bleeding or abortion."
3.	Hyponatremia 12/01/1984 - "As the prostaglandin analogue effectively blocked the antidiuretic effect of the AVP-administration it appears that 9-methylene-PGE2 may play a future role as a diuretic agent, especially in conditions characterized by water retention and dilutional hyponatremia such as SIADH."
4.	Bartter Syndrome (Syndrome, Bartter) 12/01/1984 - "However the protocol followed did not provide any evidence for this, or any other explanation of the observed renal retention of Na+, Ca2+ and Mg2+. The results reported here indicate that 9-methylene-PGE2 may have a future use as a water diuretic agent in patients suffering from water retention and dilutional hyponatraemia such as seen in the syndrome of inappropriate antidiuretic hormone (AVP) release commonly known as SIADH or Schwartz-Bartter's Syndrome."
5.	Amenorrhea 10/01/1990 - "Termination of early pregnancy (49 days of amenorrhea) was induced in 75 patients with the combination of the antigestagen mifepristone and a prostaglandin (PG) analogue, meteneprost. " 10/01/1990 - "Termination of early pregnancy (less than 49 days of amenorrhea) was induced in 75 patients with the combination of the antigestagen mifepristone and a prostaglandin analogue, meteneprost. "

Related Drugs and Biologics

1.	Synthetic Prostaglandins (Prostaglandin Analogues)
2.	Diuretics
3.	Antidiuretic Agents
4.	Mifepristone (RU 486)
5.	Vasopressins (Vasopressin)
6.	Prostaglandins